LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

被引：18
|
作者：
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134970
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
  • [2] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    Wang, Michael
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan Ni
    Lewis, Katharine L.
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian W.
    Lewis, David John
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Jonathon B.
    Barve, Minal
    Ghia, Paolo
    Eyre, Toby A.
    Yin, Ming
    Nair, Binoj
    Tsai, Donald
    Ku, Nora C.
    Mato, Anthony
    Cheah, Chan Yoon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
  • [3] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
    Coombs, Catherine C.
    Pagel, John M.
    Shah, Nirav N.
    Lamanna, Nicole
    Lech-Maranda, Ewa
    Eyre, Toby A.
    Woyach, Jennifer A.
    Wierda, William G.
    Cheah, Chan Y.
    Roeker, Lindsey
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine S.
    Lewis, David J.
    Gerson, James N.
    Alencar, Alvaro
    Taylor, Justin
    Abdel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen J.
    Chen, Jessica
    Nair, Binoj
    Tsai, Donald E.
    Ku, Nora C.
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    Mato, Anthony R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S315 - S316
  • [4] Pirtobrutinib; A Next Generation; Highly Selective; Non-covalent BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
    Pagel, John M.
    Coombs, Catherine C.
    Shah, Nirav N.
    Lamanna, Nicole
    Lech-Maranda, Ewa
    Eyre, Toby A.
    Woyach, Jennifer A.
    Weirda, William G.
    Cheah, Chan Y.
    Roeker, Lindsey E.
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine
    Lewis, David
    Gerson, James N.
    Alencar, Alvaro J.
    Ghia, Paolo
    Schuster, Stephen J.
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    Mato, Anthony R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 168 - 169
  • [5] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results fro the Phase 1/2 BRUIN Study
    Mato, Anthony R.
    Pagel, John M.
    Coombs, Catherine C.
    Shah, Nirav N.
    Lamanna, Nicole
    Munir, Tahla
    Lech-Maranda, Ewa
    Eyre, Toby A.
    Woyach, Jennifer A.
    Wierda, William G.
    Cheah, Chan Yoon
    Cohen, Jonathon B.
    Roeker, Lindsey E.
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine S.
    Lewis, David John
    Gerson, James N.
    Alencar, Alvaro J.
    Ujjani, Chaitra S.
    Flinn, Ian W.
    Sundaram, Suchitra
    Ma, Shuo
    Jagadeesh, Deepa
    Rhodes, Joanna M.
    Taylor, Justin
    Abdel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen J.
    Wang, Denise
    Nair, Binoj
    Zhu, Edward
    Tsai, Donald
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    BLOOD, 2021, 138
  • [6] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
    Coombs, Catherine C.
    Pagel, John M.
    Shah, Nirav N.
    Lamanna, Nicole
    Munir, Talha
    Lech-Maranda, Ewa
    Eyre, Toby A.
    Woyach, Jennifer A.
    Wierda, William G.
    Cheah, Chan Y.
    Cohen, Jonathon B.
    Roeker, Lindsey E.
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine S.
    Lewis, David
    Gerson, James N.
    Alencar, Alvaro
    Ujjani, Chaitra
    Flinn, Ian
    Sundaram, Suchitra
    Ma, Shuo
    Jagadeesh, Deepa
    Rhodes, Joanna
    Taylor, Justin
    Abdel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen J.
    Wang, Denise
    Nair, Binoj
    Zhu, Edward
    Tsai, Donald E.
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    Mato, Anthony R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
  • [7] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
    Mato, Anthony
    Pagel, John
    Coombs, Catherine
    Shah, Nirav
    Lamanna, Nicole
    Munir, Talha
    Lech-Maranda, Ewa
    Eyre, Toby
    Woyach, Jennifer
    Wierda, William
    Cheah, Chan
    Cohen, Johnathan
    Roeker, Lindsey
    Patel, Manish
    Fakhri, Bita
    Barve, Minal
    Tam, Constantine
    Lewis, David
    Gerson, James
    Alencar, Alvaro
    Ujjani, Chaitra
    Flinn, Ian
    Sundaram, Suchitra
    Ma, Shuo
    Jagadeesh, Deepa
    Rhodes, Joanna
    Taylor, Justin
    Abdel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen
    Wang, Denise
    Nair, Binoj
    Zhu, Edward
    Tsai, Donald
    Davids, Matthew
    Brown, Jennifer
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
  • [8] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
    Wang, Michael
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan Ni
    Lewis, Katharine L.
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian W.
    Lewis, David John
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Jonathon B.
    Barve, Minal
    Ghia, Paolo
    Eyre, Toby A.
    Yin, Ming
    Nair, Binoj
    Tsai, Donald
    Ku, Nora C.
    Mato, Anthony
    Cheah, Chan Yoon
    BLOOD, 2020, 136
  • [9] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14
  • [10] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
    Eyre, Toby
    Pagel, John M.
    Coombs, Catherine C.
    Shah, Nirav N.
    Lamanna, Nicole
    Lech-Maranda, Ewa
    Woyach, Jennifer
    Wierda, William G.
    Cheah, Chan Y.
    Roeker, Lindsey
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine S.
    Lewis, David
    Gerson, James N.
    Alencar, Alvaro
    Taylor, Justin
    Abedel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen J.
    Chen, Jessica
    Nair, Binoj
    Tsai, Donald E.
    Ku, Nora C.
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 37 - 38
12345